Get the Stockscreener App
17.21
0.52%
-0.09
After Hours:
17.21
Bausch Lomb Corp stock is traded at $17.21, with a volume of 290.69K.
It is down -0.52% in the last 24 hours and up +4.56% over the past month.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
See More
Previous Close:
$17.30
Open:
$17.31
24h Volume:
290.69K
Relative Volume:
0.67
Market Cap:
$6.10B
Revenue:
$4.89B
Net Income/Loss:
$-263.00M
P/E Ratio:
-22.25
EPS:
-0.7734
Net Cash Flow:
$-167.84M
1W Performance:
+3.80%
1M Performance:
+4.56%
6M Performance:
+22.49%
1Y Performance:
-4.81%
1-Day Range:
$17.08
$17.43
1-Week Range:
$16.22
$17.55
52-Week Range:
$10.45
$18.14
Bausch Lomb Corp Stock (BLCO) Company Profile
Name
Bausch Lomb Corp
Sector
Industry
Phone
908-541-5456
Address
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
17.21 | 6.13B | 4.89B | -263.00M | -167.84M | -0.7734 |
|
ISRG
Intuitive Surgical Inc
|
586.24 | 207.41B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
202.75 | 58.46B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.13 | 39.60B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
252.47 | 36.63B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
MDLN
Medline Inc
|
40.52 | 32.47B | 27.43B | 1.27B | 1.01B | 1.5829 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-01-25 | Initiated | Goldman | Neutral |
| May-02-25 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-15-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-10-24 | Initiated | Raymond James | Outperform |
| May-06-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-12-23 | Initiated | Stifel | Hold |
| Oct-03-23 | Resumed | Evercore ISI | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-09-23 | Initiated | Needham | Hold |
| Dec-21-22 | Initiated | Barclays | Equal Weight |
| Sep-12-22 | Initiated | H.C. Wainwright | Buy |
| Jul-26-22 | Initiated | RBC Capital Mkts | Outperform |
| Jun-24-22 | Initiated | Evercore ISI | Outperform |
| Jun-06-22 | Initiated | Citigroup | Buy |
| May-31-22 | Initiated | Deutsche Bank | Hold |
| May-31-22 | Initiated | Goldman | Neutral |
| May-31-22 | Initiated | Guggenheim | Buy |
| May-31-22 | Initiated | JP Morgan | Neutral |
| May-31-22 | Initiated | Jefferies | Buy |
| May-31-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Initiated | Wells Fargo | Overweight |
| May-11-22 | Initiated | Cowen | Outperform |
View All
Bausch Lomb Corp Stock (BLCO) Latest News
Intraocular Lens Market Size to Reach USD 9.85 Billion by 2033, Growing at a CAGR of 6.48% - GlobeNewswire Inc.
Will Bausch + Lomb Corporation (S2L) stock benefit from Fed rate cutsProduct Launch & Safe Entry Momentum Tips - ulpravda.ru
Bausch + Lomb (NYSE:BLCO) Rating Lowered to "Hold" at Evercore ISI - MarketBeat
Bausch + Lomb (NYSE:BLCO) Valuation Check After Mixed 90 Day And 1 Year Shareholder Returns - Yahoo Finance
Evercore Downgrades Bausch + Lomb Corp.(BLCO.US) to Hold Rating, Cuts Target Price to $18 - 富途牛牛
Bausch + Lomb Corporation (BLCO): Investor Outlook on Growth Potential and Strategic Positioning - DirectorsTalk Interviews
Glaucoma stories and research drive new Bausch + Lomb awareness push - Stock Titan
Bausch & Lomb CorpEnters fourth amendment to credit agreement dated as of May 10, 2022SEC filing - marketscreener.com
Bausch + Lomb just refinanced $2.8B in debt to cut interest margin - Stock Titan
Bausch + Lomb Signs Fourth Amendment to Credit Agreement With JPMorgan Chase and Lenders - TradingView — Track All Markets
Bausch + Lomb (BLCO): Investor Outlook on a Visionary Healthcare Player with a Focused Growth Trajectory - DirectorsTalk Interviews
Does Bausch + Lomb’s Rising Focus on Eye Health Make Its Current Share Price Attractive? - simplywall.st
Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Top eye-care leaders to speak at J.P. Morgan's big healthcare event - Stock Titan
[8-K/A] Bausch & Lomb Corp Amends Material Event Report | BLCO SEC FilingForm 8-K/A - Stock Titan
Bausch + Lomb Corporation (NYSE:BLCO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Will Bausch + Lomb Corporation stock keep outperforming rivalsMarket Trend Summary & Reliable Breakout Forecasts - Улправда
Published on: 2025-12-18 17:17:15 - Улправда
Icahn Money Manager Sues His Bosses and Bausch + Lomb Over Anti-White Bias - Insurance Journal
Fund Exits $6.6 Million Bausch + Lomb Stake as Shares Lag by 9% This Past Year - The Globe and Mail
Bausch + Lomb Announces Refinancing of Outstanding Term B Loans - VisionMonday.com
Bausch + Lomb appoints two new directors to board effective January - Investing.com
Bausch + Lomb Adds New Directors to Board - TipRanks
Bausch & Lomb Corp Announces Board Appointments - TradingView — Track All Markets
Bausch + Lomb appoints two new directors to board effective January By Investing.com - Investing.com South Africa
Bausch + Lomb (NYSE: BLCO) appoints Eduardo Alfonso and Steven Collis to board - Stock Titan
Bausch + Lomb Brief: Appointing Eduardo C. Alfonso, and Steven H. Collis To Its Board, Effective Jan. 1, 2026; Board Will Then Be Comprised of 10 Directors - marketscreener.com
Bausch + Lomb Announces Two Board Of Directors Appointments - TradingView — Track All Markets
Leading eye specialist and Fortune 10 CEO join Bausch + Lomb board - Stock Titan
Fund Exits $6.6 Million Bausch + Lomb Stake as Shares Lag by 9% This Past Year - The Motley Fool
Bausch + Lomb Corporation's (NYSE:BLCO) Prospects Need A Boost To Lift Shares - 富途牛牛
Large-Scale Debt Refinancing And Pipeline Optimism Might Change The Case For Investing In Bausch + Lomb (BLCO) - simplywall.st
(BLCO) Strategic Equity Report (BLCO:CA) - news.stocktradersdaily.com
America First Legal Files Lawsuit Against Bausch + Lomb for Racial Discrimination in Board Appointments - America First Legal
Icahn money manager sues his bosses and Bausch + Lomb over anti-white bias - MSN
Bausch + Lomb: I Need To See Stability Before Upgrading This Name (BLCO) - Seeking Alpha
Nomura Holdings Inc. Cuts Holdings in Bausch + Lomb Corporation $BLCO - MarketBeat
Bausch + Lomb (NYSE:BLCO) valuation after analyst upgrades highlight confidence in growth and margin improvement - simplywall.st
Bausch + Lomb allocates $2.8 bln in new term loans to refinance existing debt - MSN
How Bausch + Lomb’s $2.8 Billion Refi and Eye-Care Pipeline Momentum Will Impact Bausch + Lomb (BLCO) Investors - Yahoo Finance
(BLCO) Stock Trading Blueprint (BLCO:CA) - news.stocktradersdaily.com
Bausch + Lomb Announces $2.8 Billion Loan Refinancing - TipRanks
Bausch & Lomb Corp Announces Refinancing of Term B Loans - TradingView — Track All Markets
Bausch + Lomb allocates $2.8 billion to refinance outstanding loans By Investing.com - Investing.com South Africa
Bausch + Lomb allocates $2.8 billion to refinance outstanding loans - Investing.com
Bausch + Lomb (NYSE: BLCO) announces $2,802,125,000 term B refinancing with 2031 maturity - Stock Titan
Bausch + Lomb (NYSE: BLCO) allocates $2,802,125,000 term B loans at 3.75% - Stock Titan
Citi Upgrades Bausch + Lomb Corp.(BLCO.US) to Buy Rating, Announces Target Price $20 - 富途牛牛
Bausch + Lomb Shares Rise After Citigroup Upgrade - marketscreener.com
Why Bausch + Lomb (BLCO) Stock Is Trading Up Today - Finviz
Citigroup Upgrades Bausch + Lomb to Buy From Neutral, Adjusts Price Target to $20 From $16 - marketscreener.com
Bausch Lomb Corp Stock (BLCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.30%
0.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):